D. Wirta

发表

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies

K. Sall, E. Meier, A. Narvekar, 2017, Clinical ophthalmology.

Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial.

D. Wirta, P. Vollmer, J. Paauw, 2021, Ophthalmology.

Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis

M. Jaros, M. Korenfeld, D. Wirta, 2020, JAMA ophthalmology.

Safety and Efficacy of AGN-190584 in Individuals With Presbyopia

M. Robinson, M. Moshirfar, C. Mccabe, 2022, JAMA ophthalmology.

Combinations of Pilocarpine and Oxymetazoline for the Pharmacological Treatment of Presbyopia

M. Robinson, M. Moshirfar, F. Price, 2021, Ophthalmology science.

A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare® System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease

P. Karpecki, D. Wirta, K. Dhamdhere, 2020, Clinical ophthalmology.

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

P. Steven, J. Ciolino, G. Ousler, 2019, Ophthalmology.

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)

P. Karpecki, Elizabeth Yeu, D. Wirta, 2022, Cornea.

Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study

G. Ousler, D. Wirta, E. McLaurin, 2021, Ophthalmology and Therapy.

Eyelid neuroma associated with swim goggle use.

D. Wirta, R. Dailey, J. Wobig, 1998, Archives of ophthalmology.

Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results

M. Korenfeld, D. Wirta, J. Bacharach, 2021, Clinical ophthalmology.

An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects

M. Borchert, D. Wirta, S. Bruce, 2016, Clinical ophthalmology.

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)

Dawn Y. Lim, John C. Greiner, H. Thieme, 2021, Drugs.

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

S. Whitcup, D. Wirta, A. Vandenburgh, 2011, Clinical ophthalmology.

Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.

J. Carruthers, S. Cox, J. Walt, 2013, Aesthetic surgery journal.

Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects.

L. Baumann, D. Wirta, S. Bruce, 2015, The Journal of clinical and aesthetic dermatology.

24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial.

R. Weinreb, M. Kahook, R. Fechtner, 2019, Ophthalmology.

Noninferiority Study Comparing Latanoprost 0.005% Without Versus With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension

J. Peace, K. Sall, D. Wirta, 2021, Eye & contact lens.

Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.

J. Peace, D. Wirta, James D. Branch, 2015, American journal of ophthalmology.

Maximal, three-wall, orbital decompression through a coronal approach.

R. Goldberg, D. Weinberg, D. Wirta, 1997, Ophthalmic surgery and lasers.

A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study

T. Schlüter, J. Ciolino, G. Ousler, 2021, Cornea.

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

M. Jaros, M. Korenfeld, D. Wirta, 2021, Clinical ophthalmology.

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study

Y. Kuwayama, Fenghe Lu, D. Wirta, 2022, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

'A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1).

M. Senchyna, G. Ousler, D. Hollander, 2022, The ocular surface.

A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.

Yunsheng He, C. Grosskreutz, J. Peace, 2018, American journal of ophthalmology.

Two Randomized, Double-masked, Placebo-controlled Studies of the Local Anesthetic Effect of Articaine Ophthalmic Solution

G. Novack, V. Gonzalez, D. Wirta, 2023, Clinical ophthalmology.

Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease

J. Ciolino, J. Sheppard, E. Akpek, 2023, JAMA ophthalmology.

Mydriasis with micro-array print touch-free tropicamide-phenylephrine fixed combination MIST: pooled randomized Phase III trials.

T. Ianchulev, Siddarth Rathi, D. Wirta, 2021, Therapeutic delivery.

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease

D. Hollander, D. Wirta, J. Nau, 2021, Cornea.

Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial

P. Karpecki, D. Wirta, Melissa M Toyos, 2024, BMC ophthalmology.

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease

D. Fong, J. Goldberg, T. Yednock, 2023, Ophthalmology science.

Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE.

A. Galor, D. Wirta, Alice S. Meides, 2024, Cornea.

NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.

S. Krösser, J. Tauber, D. Wirta, 2022, Ophthalmology.

A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease

E. Holland, V. Thompson, D. Wirta, 2022, Clinical ophthalmology.

A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease

P. Majmudar, K. Sall, S. Krösser, 2020, Cornea.

OPTH_A_368319 2861..2871

E. Holland, V. Thompson, D. Wirta, 2022 .